Get notified when VOGX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Material Weakness (new) — The company discloses material weaknesses in internal control over financial reporting, which could affect financial reporting reliability.
  • Going Concern (new) — The auditor's report contains an explanatory paragraph regarding the company's ability to continue as a going concern.
  • Restatement (new) — The auditor's report references a restatement of the company's financial statements, indicating past accounting errors.
  • Concentration (new) — Substantially all resources are focused on a single lead candidate, mizagliflozin, for PBH, creating high concentration risk.
  • Dilution (new) — New investors face immediate dilution of $7.76 per share, with existing stockholders having paid an average of $1.41 per share.
VOGX Vogenx, Inc. 424B4

Vogenx prices $81.2M IPO at $13/share; clinical-stage biotech with material weaknesses and going-concern warning

Filed August 12, 2026 · ~2 min read

Key Changes

  • high

    Vogenx is offering 6,250,000 shares at $13.00 per share, raising $81.2M gross for the company before underwriting discounts and expenses.

    The Offering verify on EDGAR →
  • high

    Net proceeds to the company are $84.9M if the underwriters' over-allotment option is exercised in full; base net proceeds are approximately $73.6M.

    Use of Proceeds verify on EDGAR →
  • high

    The company plans to use proceeds primarily for two Phase 2 trials of mizagliflozin: $26.3M for PBH and $20.4M for gastroparesis.

    Use of Proceeds verify on EDGAR →

4 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (DLTH 10-Q) is open in full — no account needed.

Partner

Trade VOGX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify